Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Accounts Payables: 2015-2024

Historic Accounts Payables for Cartesian Therapeutics (RNAC) over the last 10 years, with Dec 2024 value amounting to $288,000.

  • Cartesian Therapeutics' Accounts Payables rose 330.37% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year increase of 330.37%. This contributed to the annual value of $288,000 for FY2024, which is 90.86% down from last year.
  • Cartesian Therapeutics' Accounts Payables amounted to $288,000 in FY2024, which was down 90.86% from $3.1 million recorded in FY2023.
  • Over the past 5 years, Cartesian Therapeutics' Accounts Payables peaked at $3.1 million during FY2023, and registered a low of $224,000 during FY2021.
  • For the 3-year period, Cartesian Therapeutics' Accounts Payables averaged around $1.3 million, with its median value being $316,000 (2022).
  • Per our database at Business Quant, Cartesian Therapeutics' Accounts Payables spiked by 896.84% in 2023 and then crashed by 90.86% in 2024.
  • Over the past 5 years, Cartesian Therapeutics' Accounts Payables (Yearly) stood at $443,000 in 2020, then plummeted by 49.44% to $224,000 in 2021, then soared by 41.07% to $316,000 in 2022, then skyrocketed by 896.84% to $3.1 million in 2023, then slumped by 90.86% to $288,000 in 2024.